Skip to content

A Clinical Study to See Whether Adding an Ayurvedic Medicine (Chandraprabha Vati) Improves Blood Sugar Control Along with Metformin in Type 2 Diabetes

A Randomized Controlled Clinical Study to evaluate add on effect of Chandraprabhavati with Metformin in Prameha With Special Reference to Type 2 Diabetes Mellitus. - CPM-DM Trial

Status
Active, not recruiting
Phases
Phase 3Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/05/110462
Enrollment
60
Registered
2026-05-12
Start date
Unknown
Completion date
Unknown
Last updated
2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E119- Type 2 diabetes mellitus without complications

Interventions

None listed

Sponsors

YCAMC COLLEGE AND HOSPITAL Nipani Bhalgaon State Maharashtra Country India pincode
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Age group between 30 to 60 years Newely diagnosed cases of Type 2 DM and known Type 2 DM patient only on Metformin 500 mg OD Non insulin dependent diabetes mellitus Patient with fasting blood sugar between 126 - 200 mg dl and post prandial blood sugar between 140 - 350 mg dl Patient having HbA1C between 6.5 10 Patient taking Metformin 500 mg with Diet Restrictions

Exclusion criteria

Exclusion criteria: CRITERIA FOR EXCLUSION Juvenile Diabetes and Insulin Dependent Diabetes Mellitus IDDM Patients with Renal Disorders like Chronic kidney disease and Acute kidney diseases Patients with acute complications Hyperglycemic & hypoglycemic coma Ketoacidosis and related complication and Infections like gangrene Patients with chronic diabetic complications like Nephropathy Neuropathy and Retinopathy Pregnant and lactating women

Design outcomes

Primary

MeasureTime frame
To study and evaluate the add on effect of Chandraprabhavati 500 MG OD with Metformin 500 MG OD in Prameha Type ll DM for 3 months. Timepoint: BSL F and PP will be assessed after entry point 7 th 15 th 30th 60th day and end of the trial 90th Day HBA1C will assessed on Day 1 & Day 90 th of Trial

Secondary

MeasureTime frame
To observe adverse effects if anyTimepoint: Follow up on 1st week 4 th week & 12 th week

Countries

India

Contacts

Public ContactDr Meera Solanke

Shiva Trusts Yashwantrao Chavan Ayurvedic Medical College And Hospital Chhatrapati Sambhajinagar

meerasolanke20@gmail.com7447801802

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Jun 11, 2026